About the Company:
Beta Drugs Limited is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic & international customers. .
Company’smanufacturing unit is an ISO 9001:2008 certified facility located at Kharuni –Lodhimajra Road, Village Nandpur, Baddi, Dist-Solan Himachal Pradesh, and India.
Company is primarily engaged in the manufacturing of oncology products.Company’s products range from anti-cancer tablets, capsules, injections and lyophilized injections.
Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease.
As on March 31, 2017, Company had a portfolio of over 50 products catering to various oncology diseases.
Company has increased their product range, starting from 35 in 2015-16 to 50 active products in 2016-17.Company’s oncology portfolio includes key brands like Admine, Adgef, Addplatin, Erlotad etc.
Management Team:
- Mr.Vijay Kumar Batra (Designation: Managing Director)
- Mr.Balwant Singh (Designation: Whole Time Director)
- Mr.Varun Batra (Designation: Whole Time Director)
Promoters Average Acquisition Cost:
| Name of the Promoter | No. of Shares held | Average Acquisition Cost (in Rs.) |
|---|---|---|
| Vijay Batra | 5924780 | 1.80 |
Promoters Stake Pre & Post Issue:
| Shareholder Name | Pre Issue Stake (%) | Post Issue Stake |
|---|---|---|
| Promoter | ||
| Vijay Batra | 93.25% | 68.50% |
| Promoter Group Entities | 0.53% | 0.39% |
| Total | 93.78% | 68.89% |
Objectives of the Issue:
- Purchase of new plant and machinery and upgradation of company’s existing plant and machinery.
- Civil Construction work at existing manufacturing unit.
- To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operation Scheme certificate.
- Working Capital requirements.
- General Corporate Purpose.
Fund Utilization:
| Particulars | Amount (Rs. in Crores) |
|---|---|
| Purchase of new plant and machinery and upgradtion of our existing plant and machinery |
7.41 |
| Civil Construction work at existing manufacturing unit. | 1.27 |
| To obtain registration of European Union GMP & Pharmaceutical Inspection Co-operation Scheme. |
0.79 |
| Working Capital | 2.94 |
| General Corporate Purpose* | 4.09 |
| Net Proceeds | 16.5 |
| Check IPO Allotment Status: |
|---|
Link Time Websitehttps://linkintime.co.in/PublicIssues/ |
Financials of the Company:
| (in Crores) | FY 13 | FY 14 | FY 15 | FY 16 | FY 17 |
|---|---|---|---|---|---|
| Revenue | 3.12 | 1.38 | 0.26 | 26.39 | 41.68 |
| Net Profit | 0.04 | 0.02 | 0.11 | 1.13 | 5.17 |
Valuation of Peer Group Companies:
| Company Name | Face Value | CMP | EPS | PE Ratio | RoNW | NAV |
|---|---|---|---|---|---|---|
| Beta Drugs Limited |
10 | 85 | 8.69 | 9.78 | 70.18 | 12.39 |
| Venus Remedies Ltd |
10 | 91.90 | 4.14 | 22.20 | 1.04 | 370.41 |
| Natco Pharma Limited |
2 | 726.20 | 28.27 | 25.69 | 29.11 | 97.40 |
IPO Details:
| Details | Info |
|---|---|
| Issue Opens on | 29th September 2017 |
| Issue Closes on:. | 4th October 2017 |
| Issue Price | Rs.85 |
| Face Value | Rs.10 |
| Minimum Lot | 1600 |
| Minimum Investment | Rs.1,36,000 |
| Issue Constitutes | 26.54% |
| Issue Size | Rs.19.51 cr |
| Market Cap | Rs.73.52 cr |
| Listing at | NSE SME |
| Equity Shares Offered (Fresh) | 22,96,000 |
| Equity Shares Prior | 63,35,500 |
| Equity Shares after the issue | 86,49,500 |
Important Dates:
| Finalization of Basis of Alottment | on or Before 9th October 2017 |
| Initiation of Refunds | on or Before 10th October 2017 |
| Credit of Equity Shares: | on or Before 11th October 2017 |
| Listing Date: | on or Before 12th October 2017 |
IPO Valuation Parameters:
| Earnings Per Share (EPS) | Price To Earnings ratio (PE) | Return on Net Worth (RoNW) | Net Asset Value (NAV) |
|---|---|---|---|
| 8.69 | 9.78 | 50.48% | 12.39 |
Markets Guruji Opinion:
| IPO View | Apply For: | Expected listing Gain: |
|---|---|---|
| Subscribe | Short Term | 10% |
